Of note, the only RASGRF fusion we identified in a PDAC with a concurrent KRAS mutation is MSH3-RASGRF2 (which lacks the PH1 but not DH domain), suggesting the fusion is unlikely to be an oncogenic driver in that tumor (Supplementary Fig. 2). This evidence concerns the gene MSH3 and neoplasm.